A Prospective, Multicenter, Post-marketing Clinical Follow-up Research to Evaluate the Long-term Safety of Ellansé-S Dermal Filler Made of PCL Microspheres for the Correction of Moderate-to-severe Nasolabial Folds

Inclusion criteria

• 18 years old and above;
• Subjects with moderate-to-severe nasolabial folds (3-4 level of WSRS scores) on both sides of the face
• Intended to be treated with PCL microsphere filler;
• Voluntarily participate in this test, cooperate with follow-up, and sign an informed consent form

Exclusion criteria

• Obvious acne scar, pigmentation, active infection, inflammation, tumor, precancerous lesion or unhealed wound in the intended injection area;
• Patients who have used permanent fillers (PMMA, hydrogel polymer, liquid silicone for injection, polyvinyl alcohol (PVA), bone cement, autologous fat, etc.) for nasolabial groove injection;
• Patients who have received semi-permanent fillers (polycaprolactone, L-polylactic acid, hydroxyapatite, platelet-rich plasma, etc.) injection treatment in nasolabial sulch area in the past 24 months;
• Patients who have received temporary fillers (hyaluronic acid, collagen, etc.) injection treatment in nasolabial groove in the past 12 months;
• Patients who have received botox injection treatment in nasolabial sulci in the past 6 months;
• The nasolabial groove has been treated with beauty plastic, focused ultrasound, chemical stripping, photoelectric (laser, photon, radio frequency) in the past 3 months;
• Use of hormones or immunosuppressants within the past 1 month;
• Subjects who have used anticoagulants in the last 2 weeks;
• Subjects with a history of crabfoot, hyperplastic scars or cicatricial constitution;
• Subjects with active sepsis;
• Subjects with coagulation dysfunction;
• Subjects with autoimmune diseases;
• Allergic to polycaprolactone or known product ingredients;
• Pregnant, pregnant and lactating subjects;
• Participated in other clinical trials in the past 30 days;
• Other situations determined by the researcher to be unsuitable for participation in this study;